Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Common Equity: 2017-2024

Historic Common Equity for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $163.3 million.

  • Cidara Therapeutics' Common Equity rose 265.29% to $422.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $422.4 million, marking a year-over-year increase of 265.29%. This contributed to the annual value of $163.3 million for FY2024, which is 2089.14% up from last year.
  • Cidara Therapeutics' Common Equity amounted to $163.3 million in FY2024, which was up 2,089.14% from -$8.2 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Common Equity ranged from a high of $163.3 million in FY2024 and a low of -$14.4 million during FY2022.
  • Moreover, its 3-year median value for Common Equity was -$8.2 million (2023), whereas its average is $46.9 million.
  • In the last 5 years, Cidara Therapeutics' Common Equity slumped by 166.93% in 2022 and then soared by 2,089.14% in 2024.
  • Over the past 5 years, Cidara Therapeutics' Common Equity (Yearly) stood at $10.7 million in 2020, then surged by 101.33% to $21.6 million in 2021, then tumbled by 166.93% to -$14.4 million in 2022, then skyrocketed by 43.14% to -$8.2 million in 2023, then spiked by 2,089.14% to $163.3 million in 2024.